
|Articles|June 1, 2002
Pimecrolimus, tacrolimus keep in check pediatric AD
New Orleans - New long-term data with the topical immunomodulator tacrolimus(Protopic) and the skin-selective inflammatory cytokine inhibitor pimecrolimus(Elidel) demonstrate efficacy as maintenance therapies in the treatmentof atopic dermatitis in children. Data with pimecrolimus show safety andefficacy for as long as 26 weeks in infants as young as three months, LawrenceEichenfield, M.D., said at the annual meeting of the American Academy ofDermatology.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
The “6-7” Advances for Dermatologists to Look Forward to in 2026
2
Exploring Type 2 Inflammation and Psoriasis Management at Horizons in Advanced Practice
3
Quoin Targets World’s First Approval for Netherton Syndrome Therapy in Saudi Arabia
4
Soquelitinib Phase 1 Data Show Sustained Clinical Improvement With Extended Treatment in AD
5



















